



## Murat Yildiz

### Kontakt

Murat Yildiz

### Bereiche

Neurologie

## Publikationen (9)

Yildiz M, Tettenborn B, Radue E, Bendfeldt K, Borgwardt S. Association of cognitive impairment and lesion volumes in multiple sclerosis - A MRI study. *Clin Neurol Neurosurg* 2014; 127:54-8.

Yildiz M, Tettenborn B, Borgwardt S. Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients. *Clin Neurol Neurosurg* 2012; 115:902-3.

Haltmeier S, Yildiz M, Müller S, Anliker M, Heinzerling L. Contact dermatitis induced by glatiramer acetate. *Mult Scler* 2011; 17:1390-2.

Tettenborn B, Yildiz M, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. *Swiss Med Wkly* 2011

Yildiz M, Tettenborn B, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. *Swiss Med Wkly* 2011; 141:w13192.

Yildiz M, Müller S, Vehoff J, Tettenborn B (2011). Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate: 1 year follow-up.

Yildiz M, Tettenborn B, Putzki N. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. *Eur Neurol* 2011; 65:231-2.

Yildiz M, Tettenborn B, Putzki N (2010). Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate.

Yildiz M, Tettenborn B, Putzki N. Natalizumab and beyond. *Eur Neurol* 2010; 64:236-40.

## Projekte (9)

**Cohort Study comparing Corpus Callosum Atrophy as a marker of later development of cognitive impairment in patients with early and remitting relapsing multiple sclerosis**

*Klinische Forschung - 14.03.2011 - 31.05.2011*

*Abgeschlossen*

**Neurocognitive changes in patients with relapsing multiple sclerosis treated with Natalizumab**

*Klinische Forschung - 01.01.2011 - 31.12.2012*

*Abgeschlossen*

**Tenere: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis**

*Klinische Forschung - 03.05.2010 - 30.06.2011*

*Abgeschlossen*

**Fatigue in Multiple Sclerosis now and then: a cross-sectional study**

*Klinische Forschung - 30.11.2009 - 30.04.2009*

*Abgeschlossen*

**Selective S1P1 receptor agonist in Patients with Relapsing-Remitting Multiple Sclerosis**

*Klinische Forschung - 01.11.2009 - 01.11.2010*

*Abgeschlossen*

**Subkutane Mehrfachdosierungen von LY2127399, einem menschlichen Anti-BAFF-Antikörper, bei Patienten mit schubförmig remittierender multipler Sklerose**

*Klinische Forschung - 01.11.2009 - 01.05.2011*

*Abgebrochen*

**The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis**

*Klinische Forschung - 24.09.2009 - 24.09.2011*

*Automatisch geschlossen*

**A prospective MR spectroscopy study to investigate axonal loss in different stages of multiple sclerosis**

*Klinische Forschung - 24.07.2009 - 24.09.2011*

*Abgeschlossen*

**A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate (BG00012) in Subjects with Relapsing-Remitting Multiple Sclerosis**

*Klinische Forschung - 01.10.2008 - 01.12.2010*

*Abgeschlossen*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)